Understand the source comparison
DSIP Dosage Guide: Research vs Clinical Comparison
Typical Dose Range 25–50 mcg IV 60–100 mcg subcutaneous IV requires lower dose due to 100% bioavailability; subcutaneous ~60–70% bioavailability Contemporary protocols favor subcutaneous for multi-day studies due to ease of administration and lower adverse eve
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Typical Dose Range
- 25–50 mcg IV
- 60–100 mcg subcutaneous
- IV requires lower dose due to 100% bioavailability; subcutaneous ~60–70% bioavailability
- Contemporary protocols favor subcutaneous for multi-day studies due to ease of administration and lower adverse event rate
- Injection Timing
- 30 minutes pre-sleep phase
- Daily, timed to subject circadian phase (ZT12–ZT14 in nocturnal models)
- Circadian phase matters more than clock time; mistimed injections produce inconsistent or null results
- DSIP amplifies endogenous circadian signals. Timing relative to biological night is critical for reproducibility
- Protocol Duration
- Single dose or 3–5 consecutive nights
- 7–21 days for neuroprotective or chronic stress models
- Acute vs chronic exposure produces different mechanisms; sleep studies use short protocols, stress/neuroprotection requires ≥7 days
- Single-dose studies examine different biology than chronic exposure. Dose and duration must match research question
- Reconstitution Stability
- Not extensively documented in early studies
- 28 days at 2–8°C in bacteriostatic water
- Temperature excursions above 8°C cause rapid degradation; avoid freeze-thaw cycles post-reconstitution
- Storage discipline is non-negotiable. A degraded peptide at correct dose produces worse results than a stable peptide at suboptimal dose